WO2003018004A3 - Analgetic pyrroline derivatives - Google Patents
Analgetic pyrroline derivatives Download PDFInfo
- Publication number
- WO2003018004A3 WO2003018004A3 PCT/US2002/027936 US0227936W WO03018004A3 WO 2003018004 A3 WO2003018004 A3 WO 2003018004A3 US 0227936 W US0227936 W US 0227936W WO 03018004 A3 WO03018004 A3 WO 03018004A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analgetic
- structural analogs
- pyrroline derivatives
- administration
- methadone metabolites
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002458015A CA2458015A1 (en) | 2001-08-29 | 2002-08-29 | Analgetic pyrroline derivatives |
AU2002326806A AU2002326806B2 (en) | 2001-08-29 | 2002-08-29 | Analgetic pyrroline derivatives |
JP2003522524A JP2005525293A (en) | 2001-08-29 | 2002-08-29 | Analgesics and methods of use |
EP02761550A EP1420781A2 (en) | 2001-08-29 | 2002-08-29 | Analgetic pyrroline derivatives |
US10/501,692 US20070129434A1 (en) | 2002-08-29 | 2004-07-15 | Analgesics and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31553001P | 2001-08-29 | 2001-08-29 | |
US60/315,530 | 2001-08-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/501,692 Continuation US20070129434A1 (en) | 2002-08-29 | 2004-07-15 | Analgesics and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003018004A2 WO2003018004A2 (en) | 2003-03-06 |
WO2003018004A3 true WO2003018004A3 (en) | 2003-05-22 |
Family
ID=23224847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/027936 WO2003018004A2 (en) | 2001-08-29 | 2002-08-29 | Analgetic pyrroline derivatives |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1420781A2 (en) |
JP (1) | JP2005525293A (en) |
CN (2) | CN1612732A (en) |
AU (1) | AU2002326806B2 (en) |
CA (1) | CA2458015A1 (en) |
WO (1) | WO2003018004A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2013136851A (en) * | 2011-01-07 | 2015-02-20 | Таргасепт, Инк. | NON-COMPETITIVE NICOTINE RECEPTOR ANTAGONISTS |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
JP2015519333A (en) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | Compositions and methods for the treatment of neurological disorders |
CN104603096A (en) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168000A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
AU2013264896A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175357A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory bowel disease |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
EP2892878A4 (en) | 2012-09-08 | 2016-02-24 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
AU2014407862B2 (en) | 2014-09-29 | 2020-03-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN107108535B (en) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | Three-component salts of monomethyl fumarate with piperazine or ethylenediamine for the treatment of multiple sclerosis |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB915456A (en) * | 1959-07-27 | 1963-01-16 | Ernst Boehringer | Salts of substituted pyrrolidines and compositions containing them |
GB928007A (en) * | 1960-06-03 | 1963-06-06 | Ernst Boehringer | Substituted pyrrolidines |
US3149123A (en) * | 1961-01-04 | 1964-09-15 | Parke Davis & Co | 1, 3-dialkyl-3-oxyphenylpyrrolidine compounds |
GB1401048A (en) * | 1971-08-23 | 1975-07-16 | Sandoz Ltd | Spiro-indan-1,3-pyrrolidines |
US4005103A (en) * | 1973-09-27 | 1977-01-25 | Societe Anonyme Dite: Hexachimie | Pyrrolidine derivatives |
-
2002
- 2002-08-29 CN CNA028169824A patent/CN1612732A/en active Pending
- 2002-08-29 WO PCT/US2002/027936 patent/WO2003018004A2/en active IP Right Grant
- 2002-08-29 EP EP02761550A patent/EP1420781A2/en not_active Withdrawn
- 2002-08-29 CN CN200910168311A patent/CN101675926A/en active Pending
- 2002-08-29 CA CA002458015A patent/CA2458015A1/en not_active Abandoned
- 2002-08-29 AU AU2002326806A patent/AU2002326806B2/en not_active Ceased
- 2002-08-29 JP JP2003522524A patent/JP2005525293A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB915456A (en) * | 1959-07-27 | 1963-01-16 | Ernst Boehringer | Salts of substituted pyrrolidines and compositions containing them |
GB928007A (en) * | 1960-06-03 | 1963-06-06 | Ernst Boehringer | Substituted pyrrolidines |
US3149123A (en) * | 1961-01-04 | 1964-09-15 | Parke Davis & Co | 1, 3-dialkyl-3-oxyphenylpyrrolidine compounds |
GB1401048A (en) * | 1971-08-23 | 1975-07-16 | Sandoz Ltd | Spiro-indan-1,3-pyrrolidines |
US4005103A (en) * | 1973-09-27 | 1977-01-25 | Societe Anonyme Dite: Hexachimie | Pyrrolidine derivatives |
Non-Patent Citations (10)
Title |
---|
BIOCHEMICAL PHARMACOLOGY (1976), 25(14), 1684-6 * |
CAVALLA ET AL.: "Analgetics based on the pyrrolidine ring", J.MED.CHEM., vol. 8, 1964, pages 316 - 326, XP002228897 * |
CHEMICAL ABSTRACTS, vol. 86, no. 7, 14 February 1977, Columbus, Ohio, US; abstract no. 37820, BRASE, DAVID A. ET AL: "Comparison of the inhibition of 5-hydroxytryptamine uptake by methadone and its congeners in human platelets" XP002228901 * |
CHEMICAL ABSTRACTS, vol. 91, no. 11, 10 September 1979, Columbus, Ohio, US; abstract no. 83167, GORCZYCA, MARIA ET AL: "Synthesis and pharmacological properties of 1,3-substituted and 5-substituted 2-pyrrolidinones" XP002228900 * |
POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY (1978), 30(5), 675-83 * |
POUPAERT ET AL.: "Structure-Activity Relationships of phenytoin-like anticonvulsant drugs", J.MED.CHEM., vol. 27, 1984, pages 76 - 78, XP002228898 * |
RUI X ET AL: "Synthesis and Analgesic Activity of Epibatidine Analogues", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 3, 6 February 1996 (1996-02-06), pages 279 - 282, XP004135077, ISSN: 0960-894X * |
TONDER J E ET AL: "AGONISTS AT THE ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTORS: STRUCTURE-ACTIVITY RELATIONSHIPS AND MOLECULAR MODELLING", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, 2001 - May 2001 (2001-05-01), pages 651 - 674, XP001106484, ISSN: 0929-8673 * |
XIAO Y ET AL: "Noncompetitive inhibition of rat alpha3/beta4 neuronal nicotinic acetylcholine receptor (nAChR) function by both enantiomers of methadone, A mu opioid receptor agonist.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience.;Miami Beach, Florida, USA; October 23-28, 1999, pages 1240, XP009003070, ISSN: 0190-5295 * |
XIAO YINGXIAN ET AL: "Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 299, no. 1, October 2001 (2001-10-01), pages 366 - 371, XP002228899, ISSN: 0022-3565 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003018004A2 (en) | 2003-03-06 |
AU2002326806B2 (en) | 2007-07-19 |
CN101675926A (en) | 2010-03-24 |
CN1612732A (en) | 2005-05-04 |
CA2458015A1 (en) | 2003-03-06 |
EP1420781A2 (en) | 2004-05-26 |
JP2005525293A (en) | 2005-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003018004A3 (en) | Analgetic pyrroline derivatives | |
WO1999039694A3 (en) | Compositions containing organic compounds | |
HUP0104795A3 (en) | Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use | |
AU3136897A (en) | Compositions, methods and devices for the transdermal delivery of drugs | |
EP1391200A4 (en) | Drug preparations | |
WO2003002136A3 (en) | Stable formulation of modified glp-1 | |
AU2002236647A1 (en) | Method and device for administering medication and/or placebo | |
AU2003228654A1 (en) | Compositions and methods for preventing abuse of orally administered medications | |
WO2002008217A3 (en) | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | |
IL136732A0 (en) | Camptothecin tetracyclic analogues, preparation, methods, applications as medicines and pharmaceutical compositions containing them | |
EE200200399A (en) | The Pyrrole Line Compound, its Preparation and its Use for the preparation of a lipid and cholesterol lowering medicament, and a pharmaceutical composition containing it | |
AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
AU2001235737A1 (en) | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | |
IL154096A0 (en) | Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
WO2002011724A3 (en) | Neuroprotective 2-pyridinamine compositions and related methods | |
WO2002012198A3 (en) | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | |
WO2003051398A8 (en) | Parenteral composition of paracetamol | |
WO2001052855A3 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
AU2001292331A2 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
AU2001292331A1 (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
AU2001275821A1 (en) | Anti-cancer composition composed of anti-cancer and anti-malarial drugs | |
AU2002358418A1 (en) | Pharmaceutical preparation containing micro-encapsulated or nano-encapsulated ginsenosides | |
WO2000048445A3 (en) | Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence | |
EP1476174A4 (en) | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same | |
AU3560601A (en) | Novel isoquinoline derivatives, preparation method and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002326806 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002761550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2458015 Country of ref document: CA Ref document number: 2003522524 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028169824 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002761550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10501692 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10501692 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002326806 Country of ref document: AU |